Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma

Table 4 Summary of previous studies

Ref.	Country	Number of HCC/CC patients	1-year survival (%)	3-year survival (%)	Factors predictive of survival
Park et al[32], 2013	South Korea	Hepatic resection (n = 10)	20	20	Age, sex, TACE and T stage by univariate analysis, but none multivariate analysis
Antwi et al[33], 2018	United States	Liver transplant (n = 19)	84	74	Response to neoadjuvant LRT
Groeschl et al[31], 2013	United States	Hepatic resection (n = 35); Liver transplant (n = 19)	Resection: 71; Transplant: 89	Resection: 46; Transplant: 48	NA
Itoh et al[29], 2015	Japan	Living donor transplant (n = 8)	87.5	72.9	NA
Li et al[30], 2018	Meta-analysis	Hepatic resection (n = 1390); Liver transplant (n = 301)	Resection: 79; Transplant: 85	Resection: 63; Transplant: 63	Vascular invasion, lymph node involvement, tumor size > 5 cm and advanced stage

HCC/CC: Combined hepatocellular and cholangiocarcinoma; TACE: Transarterial chemoembolization; LRT: Locoregional therapy; NA: Not available.